Meeting
2015 ASCO Annual Meeting
Effect of somatic mutations in the four genes of the HER family on occurrence in HER2-positive breast cancer, cell proliferation rates, and resistance to HER2-targeted therapies in vitro.
Authors
Naomi Elster
Medical Oncology, Royal College of Surgeons in Ireland, Dublin, Ireland
Naomi Elster , Alex J Eustace , Yue Fan , Jarushka Naidoo , Joanna Fay , Elaine Kay , Aoife Carr , Oscar S. Breathnach , Patrick G. Morris , William Grogan , Arnold D. Hill , Colm Power , Michael J Allen , Susan Kennedy , John Crown , William M. Gallagher , Sinead Toomey , Bryan Hennessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Citation
J Clin Oncol 33, 2015 (suppl; abstr 615)
DOI
10.1200/jco.2015.33.15_suppl.615
Abstract #
615
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
First Author: Sinead Toomey
Poster
2018 ASCO Annual Meeting
An explorative phase 2 study of afatinib for advanced cancers carrying an EGFR, a HER2 or a HER3 mutation: A Precision trial of the Belgian Society of Medical Oncology.
First Author: Lore Decoster
Poster
2016 Gastrointestinal Cancers Symposium
Frequency of HER2 mutations and amplification in GI malignancies and ability of pertuzumab to overcome neuregulin1 mediated drug resistance to a HER2 tyrosine kinase inhibitor in colon cancer.
First Author: Ron Bose
Poster
2014 Gastrointestinal Cancers Symposium
Expression relationships among EGFR family members and c-Met in esophagogastric adenocarcinoma.
First Author: Ellie Chan